CSIMarket
 
Zai Lab Limited  (ZLAB)
Other Ticker:  
 
 
Price: $18.4700 $-1.08 -5.524%
Day's High: $19.44 Week Perf: -7.7 %
Day's Low: $ 18.38 30 Day Perf: -4.74 %
Volume (M): 545 52 Wk High: $ 40.42
Volume (M$): $ 10,068 52 Wk Avg: $27.32
Open: $18.86 52 Wk Low: $17.69



 Market Capitalization (Millions $) 17,658
 Shares Outstanding (Millions) 956
 Employees 656
 Revenues (TTM) (Millions $) 267
 Net Income (TTM) (Millions $) -335
 Cash Flow (TTM) (Millions $) -218
 Capital Exp. (TTM) (Millions $) 8

Zai Lab Limited
Zai Lab Limited (ZLAB) is a Chinese biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of oncology, autoimmune, and infectious diseases. The company was founded in 2014 by Dr. Samantha Du, an experienced pharmaceutical executive with a proven track record of successful drug development and commercialization.

Zai Lab has a broad pipeline of product candidates that target a range of diseases, including several late-stage clinical programs that are approaching commercialization. The company's lead product candidate is Zejula, a PARP inhibitor that is currently in Phase III clinical trials for the treatment of ovarian cancer. The company is also developing other oncology drugs, including novel kinase inhibitors and immuno-oncology therapies.

In addition to its oncology pipeline, Zai Lab has several product candidates in development for autoimmune diseases, such as atopic dermatitis and rheumatoid arthritis, as well as infectious diseases, such as COVID-19 and hepatitis B.

Zai Lab has a strong track record of partnership and collaboration with leading biopharmaceutical companies, including Sanofi, Bristol Myers Squibb, and GlaxoSmithKline. These partnerships have provided Zai Lab with access to key technologies and expertise, and have helped to accelerate the development of its product candidates.

The company aims to become a leading biopharmaceutical company in China, and has invested heavily in building a world-class research and development infrastructure. This includes state-of-the-art laboratories and manufacturing facilities, as well as a team of experienced scientists and researchers.

Zai Lab has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has a solid balance sheet, with over $1 billion in cash, cash equivalents, and short-term investments as of March 31, 202

In summary, Zai Lab Limited is a rapidly growing Chinese biopharmaceutical company with a portfolio of innovative product candidates in oncology, autoimmune diseases, and infectious diseases. The company has established strong partnerships with leading biopharmaceutical companies and has invested heavily in research and development infrastructure. With a strong financial position and a growing pipeline of product candidates, Zai Lab is well-positioned for continued success in the biopharmaceutical industry.


   Company Address: 4560 Jinke Road Shanghai 201210
   Company Phone Number: 6163 2588   Stock Exchange / Ticker: 0 ZLAB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Zai Lab Presents Promising Outcomes of ZEJULA in Phase 3 NORA Study for Platinum-Sensitive Recurrent Ovarian Cancer

Published Wed, Mar 6 2024 9:01 PM UTC

Zai Lab Limited, a leading biopharmaceutical company, has recently revealed the highly anticipated results from the Phase 3 NORA study, evaluating the efficacy and safety of their innovative drug, ZEJULA (niraparib), in Chinese patients diagnosed with platinum-sensitive recurrent ovarian cancer (PSROC). These findings, to be presented at prominent medical conferences in 2024...

Zai Lab Limited

Subheadline: Investors Concerned as Zai Lab Limited Reports Increasing Deficit Despite Revenue Growth

Zai Lab Limited (ZLAB) has been facing some serious financial challenges in the recent months, as evidenced by their increasing deficit and declining revenue numbers. The company reported a deficit per share of $-0.10 for the October to December 31, 2023 financial time-frame, a significant increase from the $-0.03 per share reported a year before. This represents a clear downward trend in the company's financial performance.
Furthermore, the company's revenue only grew by 5.16% to $65.83 million from $62.60 million in the corresponding reporting period a year before, and sequentially, the revenue actually decreased by -4.908% from $69.23 million. This stagnant revenue growth combined with the increasing deficit is a major red flag for investors.

Product Service News

Repotrectinib Shows Promise in Advanced ROS1 Fusion-Positive NSCLC Patients: Published in The New England Journal of Medicine

Published Wed, Jan 10 2024 10:12 PM UTC

Zai Lab's Repotrectinib Shows Promising Results in Treating ROS1 Fusion-Positive NSCLC, Published in The New England Journal of MedicineShanghai and Cambridge, Mass. - Zai Lab Limited, a leading biopharmaceutical company (NASDAQ: ZLAB; HKEX: 9688), has announced that The New England Journal of Medicine (NEJM) has published data from its registrational Phase 1/2 TRIDENT-1 stu...

Product Service News

Zai Lab Sees Breakthrough with VYVGART?s Inclusion in China?s 2023 National Reimbursement Drug List

Published Wed, Dec 13 2023 4:10 AM UTC


In a path-forward moment for Zai Lab Limited, the biotech firm announced today that the 2023 National Reimbursement Drug List (NRDL), released by China's National Healthcare Security Administration (NHSA), now includes VYVGART (efgartigimod alfa injection) along with several other new entries for the first time. This milestone signifies progress into previously uncharte...

Zai Lab Limited

1- Major Pharmaceutical Preparations Company's Revenue Surges in Third Quarter of 2023 Effort

The stock market has witnessed some exciting developments in the recent fiscal time-frame, specifically for Zai Lab Limited (ZLAB). Despite the challenges faced by the Major Pharmaceutical Preparations industry, ZLAB has emerged as a standout performer, demonstrating impressive growth and improvement across multiple key metrics.
First and foremost, ZLAB has managed to significantly reduce its loss per share, from $-0.17 in the previous year to a much lower $-0.07 per share. This shows the company's dedication to enhancing its financial performance and delivering value to its shareholders. Additionally, ZLAB has reported an improvement in its earnings per share (EPS), rising from $-0.13 in the preceding reporting period.






 

Zai Lab Limited's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Zai Lab Limited does not provide revenue guidance.

Earnings Outlook
Zai Lab Limited does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com